Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029585 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer
A Phase 2 study, sponsored by NanOlogy.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03029585 is a Phase 2 study that was terminated before completion, run by NanOlogy. The registered enrollment target is 10 participants.
The verdict
NCT03029585, a Phase 2 study, was terminated before completion, sponsored by NanOlogy.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will evaluate NanoPac® administered intraperitoneally (IP) immediately post-cytoreductive surgery, followed by standard of care (SOC) intravenous (IV) chemotherapy, in women with ovarian cancer. The study will compare IP NanoPac® (plus IV chemotherapy) with SOC IV chemotherapy alone.
Interventions
- DRUG NanoPac® 100 mg/m2
- DRUG NanoPac® 200 mg/m2
- DRUG NanoPac® 300 mg/m2
- DRUG NanoPac® 400 mg/m2
- DRUG Standard of Care Intravenous Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-04-19 |
| Est. Completion | 2019-11-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03029585
The ClinicalTrials.gov registry entry for NCT03029585 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NanOlogy, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which NanoPac® 100 mg/m2 is the first listed.
NCT03029585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03029585 about?
NCT03029585 is a clinical study titled "Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer". This study will evaluate NanoPac® administered intraperitoneally (IP) immediately post-cytoreductive surgery, followed by standard of care (SOC) intravenous (IV) chemotherapy, in women with ovarian cancer. The study will compare IP NanoPac® (plus IV chemotherapy) with SOC IV chemotherapy alone.
What is the current status of trial NCT03029585?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-04-19. Estimated completion is 2019-11-04.
What interventions are being tested in trial NCT03029585?
The interventions under investigation include: NanoPac® 100 mg/m2 (DRUG), NanoPac® 200 mg/m2 (DRUG), NanoPac® 300 mg/m2 (DRUG), NanoPac® 400 mg/m2 (DRUG), Standard of Care Intravenous Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03029585?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.